NcXHF

BARRIOS, WERUTSKY, AND MARTINEZ-MESA
and ethical assurances must be secured. Human participation
in clinical research is essential to advance medicine and
public health, and expanding clinical trials mandates constant
oversight to ensure research quality and protection of
study subjects. Some decades ago, the development of global
clinical research could have been considered a dream; it is
now a pressing need that should be considered unavoidable
in the future.
Disclosures of Potential Conflicts of Interest
Relationships are considered self-held and compensated unless otherwise noted. Relationships marked “L” indicate leadership positions. Relationships marked “I” are those held by an immediate
family member; those marked “B” are held by the author and an immediate family member. Institutional relationships are marked “Inst.” Relationships marked “U” are uncompensated.
Employment: None. Leadership Position: None. Stock or Other Ownership Interests: None. Honoraria: Carlos H. Barrios, GSK, Novartis, Pfizer,
Roche/Genentech, Sanofi. Consulting or Advisory Role: Carlos H. Barrios, Astellas Pharma, Boehringer Ingelheim, gsk, Novartis, Roche/Genentech.
Speakers’ Bureau: None. Research Funding: Carlos H. Barrios, Novartis, Pfizer. Patents, Royalties, or Other Intellectual Property: None. Expert
Testimony: None. Travel, Accommodations, Expenses: Carlos H. Barrios, GlaxoSmithKline, GlaxoSmithKline, Novartis, Roche/Genentech, Sanofi. Other
Relationships: None.
References
1. FinancialTimes.Defınitionofglobalization.http://lexicon.ft.com/Term?
termglobalisation. Accessed January 28, 2015.
2. Drain PK, Robine M, Holmes KK, et al. Trail watch: global migration of
clinical trials. Nat Rev Drug Discov. 2014;13:166-167.
3. Getz AK. Global clinical trials activity in the details. 2007. http://
www.appliedclinicaltrialsonline.com/node/230040?relcanonical. Accessed
January 28, 2015.
4. Glickman SW, McHutchison JG, Peterson ED, et al. Ethical and scientifıc
implications of the globalization of clinical research. N Engl J Med.
2009;360:816-823.
5. Thiers FA, Sinskey AJ, Ernst R. Trends in the globalization of clinical
trials. Nature Reviews Drug Discovery. 2008;7:13-14.
6. ClinicalTrials.gov. https://clinicaltrials.gov/. Accessed February 2, 2015.
7. Schilsky RL. Personalizing cancer care: American Society of Clinical
Oncology presidential address 2009. J Clin Oncol. 2009;27:3725-3730.
8. Breast International Group. Cancer clinical research in Latin America
must be considered as a priority. http://www.bigagainstbreastcancer.
org/news/cancer-clinical-research-latin-america-must-be-consideredpriority.
Accessed February 2, 2015.
9. Manne S, Kashy D, Albrecht T, et al. Attitudinal barriers to participation
in oncology clinical trials: factor analysis and correlates of barriers. Eur
J Cancer Care (Engl). 2015;24:28-38. Epub 2014 Jan 28.
10. Sharrocks K, Spicer J, Camidge DR, et al. The impact of socioeconomic
status on access to cancer clinical trials. Br J Cancer. 2014;111:1684-
1687.
11. Bansal N. The opportunities and challenges in conducting clinical trials
globally. Clin Res Regul Aff. 2012;29:9-14.
12. Rowland C. Clinical trials seen shifting overseas. Int J Health Serv. 2004;
34:555-556.
13. Smith WT. FDA requires foreign clinical studies be in accordance with
good clinical practices to better protect human subjects. ABA Health
eSource. 2008;5:1-3.
14. Kaitin KI. The Landscape for pharmaceutical innovation: drivers of
cost- effective clinical research. Pharm Outsourcing. 2010;2010:
3605.
15. “Investigational New Drug Application,” 21 USCFR. Food and Drugs,
Chapter I. Food and Drug Administration, Department of Health and
Human Services, part 312. Washington, DC: US Code of Federal Regulations;
2006.
16. Bjornsson TD, Wagner JA, Donahue SR, et al. A review and assessment
of potential sources of ethnic differences in drug responsiveness. J Clin
Pharmacol. 2003;43:943-967.
17. Suarez-Kurtz G. Pharmacogenetics in the Brazilian population. Front
Pharmacol. 2010;1:118. eCollection 2010.
18. Martínez-Mesa J, González-Chica DA, Bastos JL, et al. Sample size: how
many participants do I need in my research? An Bras Dermatol. 2014;
89:609-615.
19. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival
in advanced breast cancer: a review of recent randomized clinical
trials. J Clin Oncol. 2010;28:1958-1962.
20. Santosa A, Wall S, Fottrell E, et al. The development and experience of
epidemiological transition theory over four decades: a systematic review.
Glob Health Action. 2014;7:23574. eCollection 2014.
21. Nappo SA, Iafrate GB, Sanchez ZM. Motives for participating in a clinical research
trial: a pilot study in Brazil. BMC Public Health. 2013;13:19.
22. European Federation of Pharmaceutical Industries and Associations.
The Pharmaceutical Industry in Figures. Key Data 2014. Published
2014. http://www.efpia.eu/uploads/Figures_2014_Final.pdf. Accessed
February 12, 2015.
23. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic
myeloid leukemia (CML) is a reflection of the unsustainable prices of
cancer drugs: from the perspective of a large group of CML experts.
Blood. 2013;121:4439-4442. Epub 2013 April.
24. Kahneman D. Thinking Fast and Slow. New York: Farrar, Straus and
Giroux; 2011.
25. Pentz RD, White M, Harvey RD, et al. Therapeutic misconception, misestimation,
and optimism in participants enrolled in phase 1 trials.
Cancer. 2012;118:4571-4578.
26. Weinfurt KP, Seils DM, Lin L, et al. Research participants’ high expectations
of benefıt in early-phase oncology trials: are we asking the right
question? J Clin Oncol. 2012;30:4396-4400.
27. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant
chemotherapy for human epidermal growth factor receptor 2-positive
breast cancer: planned joint analysis of overall survival from NSABP
B-31 and NCCTG N9831. J Clin Oncol. 2014;32:3744-3752.
28. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy
for operable HER2-positive breast cancer. N Engl J Med.
2005;353:1673-1684.
e138
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook